search icon

    Market Snapshot

    • S&P Futures

      3,819

    • Dow Futures

      30,822

    • Nasdaq Futures

      11,785

    blog search icon

    AVEO Pharmaceuticals, Inc.

    (NASDAQ:AVEO)

    $7.17

    $0.17

    2.43%

    AVEO Pharmaceuticals, Inc. Chart

    AVEO Stock Price Today

    AVEO Pharmaceuticals, Inc. (AVEO) stock rallied over 2.43% intraday to trade at $7.17 a share on NASDAQ. The stock opened with a gain of 7.01% at $6.93 and touched an intraday high of $7.25, rising 2.43% against the last close of $7. The stock went to a low of $7 during the session.

    Stock Snapshot

    $7

    Prev. Close

    241.7 Million

    Market Cap

    $7

    Day Low

    $6.93

    Open

    34.48 Million

    Number of Shares

    $7.25

    Day High

    -

    P/E ratio

    -1.20

    EPS (TTM)

    2.53

    Cash Flow per Share

    3.12

    Free Float in %

    1.49

    Book Value

    366,282

    Volume

    AVEO Pharmaceuticals, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-07-06$6.93$7.25$7$7.17365,724
    2022-07-05$6.7$7.27$6.7$7495,500
    2022-07-01$6.56$6.74$6.53$6.71123,000
    2022-06-30$6.12$6.77$6.01$6.56365,500
    2022-06-29$6.36$6.4$6.03$6.12516,200
    2022-06-28$6.73$6.83$6.24$6.4269,200
    2022-06-27$6.5$6.89$6.36$6.67426,000
    2022-06-24$6$6.6$5.92$6.58564,100
    2022-06-23$5.26$6.15$5.2$6864,400
    2022-06-22$4.93$5.42$4.9$5.22379,500

    Contact Details

    30 Winter Street
    Boston, MA 02108
    United States

    Webiste:AVEO

    857 400 0101

    Company Information

    Employees-

    Beta0.79

    Sales or Revenue42.3 Million

    5Y Sales Change75.90%

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

    Frequently Asked Questions

    icon

    What is the current AVEO Pharmaceuticals, Inc. (AVEO) stock price?

    AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) stock price is $7.17 as of the last check on Wednesday, July 6. During the trading session, AVEO stock reached the peak price of $7.25 while $7 was the lowest point it dropped to.

    icon

    AVEO's industry and sector of operation?

    The NASDAQ listed AVEO is part of Biotechnology industry that operates in the broader Health Care sector. AVEO Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients.

    icon

    Who are the executives of AVEO?

    Ms. Danielle Holland
    Sr. Corp. Counsel & Corp. Sec.
    Mr. Kevin Peacock
    VP of Marketing
    Mr. Michael P. Bailey
    CEO, Pres & Director
    Mr. Erick Lucera CFA, CPA
    Chief Financial Officer

    icon

    What is the AVEO stock price today?

    AVEO stock traded closed the last session at $7.17, which is $0.17 or 2.43% lower than its previous close of $7. AVEO's current trading price is 134.31% lower than its 52-week high of $7.55 where as its distance from 52-week low of 3.06% is -5.03%.

    icon

    How many employees does AVEO have?

    Number of AVEO employees currently stands at -. AVEO operates from 30 Winter Street, Boston, MA 02108, United States.

    icon

    Link for AVEO official website?

    Official Webiste of $AVEO is: https://www.aveooncology.com

    icon

    How do I contact AVEO?

    AVEO could be contacted at AVEO operates from 30 Winter Street, Boston, MA 02108, United States, or at phone #857 400 0101 and can also be accessed through its website.

    icon

    How many shares of AVEO are traded daily?

    AVEO stock volume for the day was 366,282 shares while in the previous session number of AVEO shares traded was 365,724 . The average number of AVEO shares traded daily for last 3 months was 227.48 Thousands.

    icon

    How much did AVEO change today?

    The percentage change in AVEO stock occurred in the recent session was 2.43% while the dollar amount for the price change in AVEO stock was $0.17.

    icon

    What price range AVEO stock been trading in?

    In the recent session, the day high for AVEO stock was $7.25 while the low for AVEO stock touched on the day was $7.

    icon

    What is the market cap of AVEO currently?

    The market value of AVEO currently stands at 241.7 Million with its latest stock price at $7.17 and 34.48 Million of its shares outstanding.